The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Centocor, Inc.

Centocor, Inc.
 PROFILE
When the immune system fights back, Centocor is there. The Johnson & Johnson subsidiary makes the drug Remicade for autoimmune conditions Crohn's disease (a debilitating bowel disorder) and rheumatoid arthritis. It also develops cardiovascular and cancer drugs; its current offerings include ReoPro, which prevents blood clots during angioplasty; Retavase, a clot-buster used during heart attacks; Fragmin, which treats angina and prevents complications during a heart attack; and Panorex, a colorectal cancer treatment marketed only in Germany. Centocor co-markets some of its drugs with the companies from which it acquired the rights.

 COMPETITION
AstraZeneca PLC (AZN)
Aventis (AVE)
Genentech, Inc. (DNA)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1998 Sales (mil.): 338.10
1-Yr. Sales Growth: 68.4%
Employees: 1,200
Revenue per employee: $281,750.00

 KEY PEOPLE
• David P. Holveck
    CEO
• Dominic J. Caruso
    CFO

 CONTACT INFO
200 Great Valley Pkwy.
Malvern, PA 19355
US
Phone: 610-651-6000
Fax: 610-651-6100
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001